Percentagewise, it’s a common error
If a price doubles, is it 200 per cent higher? No, it’s 100 per cent higher.
medicines
Don’t count the numbers, count the spoons
The bigger a study, the better? That’s an assumption often made. But even studies that knock us out by their sheer size may be wrong.
Do antidepressants work?
Controversy over the effectiveness of antidepressants such as Prozac, provoked by an article by Irving Kirsch and colleagues in 2008 in PLOS Medicine, shows no sign of declining.
NICE and public health science challenged by MS risk sharing scheme
The most striking revelation in a quarter of comments in BMJ.com on the Department of Health’s risk sharing scheme for multiple sclerosis (MS) drugs is its undermining of subseq
NHS nil, Drug Industry 5: how not to run a risk-sharing trial
The new Government has promised to establish a system in which the price paid for drugs represents the value they bring to patients.
Cameron’s questionable cancer drug claims
Is David Cameron right to claim that people are dying because they cannot get access to cancer drugs?
Desperate Hubris: the costly, ineffectual risk sharing scheme for multiple sclerosis
Seven years ago, after strong media, clinical and patient pressure, the Government negotiated a “risk-sharing” deal over access to drugs to treat multiple sclerosis.
NICE confusion over drug uptake
The NHS Information Centre has issued some “experimental statistics” covering the take-up of medicines approved by the National Institute for health and Clinical Excellence (NICE).
